LB-LR1109 / LG Chem - LARVOL DELTA

Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC (clinicaltrials.gov) - P1 | N=76 | Recruiting | Sponsor: LG Chem | N=42 ➔ 76 | Trial completion date: Feb 2027 ➔ Mar 2028 | Trial primary completion date: Nov 2025 ➔ Nov 2027

Enrollment change • First-in-human • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer

Preclinical characterization of LG anti-LILRB1, a potent antagonist targeting LILRB1 (AACR 2025) - P1 | "Furthermore, LILRB1 blockade enhanced anti-tumor efficacy in tumor bearing LILRB1-Tg mice model. These findings suggest that LILRB1 blockade antibodies have the potential to be developed as a therapeutic agent for the cancer immunotherapy for further investigation."

IO biomarker • Preclinical • Oncology • CD69 • HLA-G • IFNG • LILRB1 • TNFRSF9

Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: LG Chem | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer

LG Chem's immuno-oncology drug wins domestic phase 1 approval (Korea Biomedical Review) - "Last Thursday, the Ministry of Food and Drug Safety (MFDS) approved a phase 1 clinical trial, in which LG Chem's immune checkpoint inhibitor candidate LB-LR1109 will be administered to humans for the first time....The trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and pharmacodynamics of LB-LR1109 in advanced or metastatic solid tumors at six medical institutions....The company received an IND from the U.S. Food and Drug Administration last December and began recruiting patients for phase 1 trials in May this year....The primary endpoints are the number of participants with dose-limiting toxicities (DLTs) and the incidence of treatment-emergent adverse events....The target primary study completion date is November 2025 with the completion deadline of February 2027."

Trial status • Solid Tumor

LG Chem company and AVEO Oncology Announce LG Chem’s First Proprietary Anti-Cancer Compound enters Phase 1 Clinical Study, Dosing Initiated in the U.S. (PRNewswire) - "'We are excited to partner with LG Chem on their first proprietary anti-cancer compound,' said Dr. Alex Spira...'There is a high unmet need for patients that have progressed on standard of care treatment which necessitates the need to explore novel immune checkpoint inhibitors such as LB-LR1109.'"

Media quote

LG Chem company and AVEO Oncology Announce LG Chem's First Proprietary Anti-Cancer Compound enters Phase 1 Clinical Study, Dosing Initiated in the U.S. (PRNewswire) - "LG Chem and AVEO Oncology, an LG Chem company, announced that it has enrolled the first patient in the United States for a Phase 1 clinical study of LB-LR1109 (NCT06332755; LG project code LR19155), LG Chem's first proprietary anti-cancer investigational drug candidate. LG Chem will be collaborating closely with AVEO Oncology, its wholly owned subsidiary, that specializes in oncology development and commercialization, to advance strategies for late-stage clinical development and regulatory approval....This is a Phase 1, multi-center, open-label, non-randomized, dose escalation study designed to determine the recommended Phase 2 dose of LB-LR1109 and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, and pharmacodynamics of LB-LR1109, and its potential impact on quality of life."

Enrollment open • Oncology • Solid Tumor

LG Chem begins US phase 1 trial for next-gen immune checkpoint inhibitor (Korea Biomedical Review) - "LG Chem said it initiated the clinical development of a next-generation immune checkpoint inhibitor to expand treatment opportunities for patients with solid tumors...The company announced on Tuesday that it has commenced patient enrollment in the phase 1 clinical trial of LB-LR1109 (project code name LR19155), its first internally developed anti-cancer medication, in the U.S...The company confirmed in animal models with solid tumors that the effectiveness of the treatment in fighting cancer is directly related to the dosage administered. This led to the U.S. FDA approval of its application for investigational new drug (IND) in December last year."

Trial status • Melanoma • Non Small Cell Lung Cancer • Renal Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer

Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors (clinicaltrials.gov) - P1 | N=42 | Not yet recruiting | Sponsor: LG Chem

Metastases • New P1 trial • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer